论文部分内容阅读
目的探讨多西他赛单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法 34例年龄>70岁的老年晚期NSCLC患者接受多西他赛60～75mg/m2静脉滴注,第1、8d,每3周重复。2周期后评价疗效。结果 34例患者中可评价疗效的有32例,其中获得CR2例,PR10例,SD14例,PD6例,总有效率为(CR+PR)37.5%,临床获益率为(CR+PR+SD)81.3%。经治疗后患者的KPS评分从75.6上升到86.8(P<0.01)。咳嗽、胸痛、气促的LCSS评分较化疗前明显升高(P<0.01)。毒副反应轻,可以耐受。结论多西他赛单药治疗老年晚期NSCLC是安全有效的,并能改善生活质量,患者耐受性好。
Objective To investigate the clinical efficacy and safety of docetaxel alone in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Methods 34 elderly patients with advanced NSCLC over 70 years old received docetaxel intravenously 60 ~ 75mg / m2 intravenously on the 1st and 8th day and repeated every 3 weeks. After 2 cycles evaluation of efficacy. Results Among the 34 patients, 32 cases were evaluable, of which CR2, PR10, SD14 and PD6 achieved a total effective rate of (CR + PR) 37.5%. The clinical benefit rate was (CR + PR + SD ) 81.3%. After treatment, the KPS score increased from 75.6 to 86.8 (P <0.01). Cough, chest pain, shortness of breath of the LCSS score was significantly higher than before chemotherapy (P <0.01). Toxic side effects, can be tolerated. Conclusion Docetaxel monotherapy is safe and effective in the treatment of advanced NSCLC, and can improve the quality of life and patient tolerance is good.